| Name | Title | Contact Details |
|---|
The Chicago Institute for Psychoanalysis is a national leader in psychoanalytic education, scholarship and clinical services to the community. The Institute educates mental health professionals as adult and child psychoanalysts and psychotherapists in its Psychoanalytic Education Program, Adult Psychotherapy Program and Child and Adolescent Psychotherapy Program. Through its clinics, the Institute provides psychotherapy on a sliding scale to adults and children, serving some of Chicago`s most vulnerable and under served communities. It also offers community education programs and consultation to schools, courts, businesses and other organizations. Institute graduates and faculty are highly skilled practitioners of psychoanalysis and psychotherapy and are the teachers, supervisors and consultants to new generations of mental health practitioners.
Center for Biomedical Continuing Education is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elmore Medical Center Foundation Inc is a Mountain Home, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.
Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.